SEC Form 4 · accession 0001209191-17-014517
HCA Healthcare, Inc. · HCA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
R Milton Johnson
Officer — Chairman & CEO · Director
Period of report
Feb 22, 2017
Accepted (ET)
Feb 24, 2017 · 6:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000860730
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 3, 2017 | G | 25,000 | $0.00 | D | 445,966 | D | |
| Common Stock | holding | — | — | — | 322,624 | I | By Trust (Spouse, Trustee) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation RightF1 | $37.18 | Feb 22, 2017 | A | 32,500 | A | Feb 22, 2017 | Feb 6, 2023 | Common Stock | 32,500 | 32,500 | D |
| Stock Appreciation RightF2 | $47.97 | Feb 22, 2017 | A | 36,500 | A | Feb 22, 2017 | Feb 5, 2024 | Common Stock | 36,500 | 36,500 | D |
Explanation of responses
- F1On February 6, 2013, the reporting person was granted 162,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2013, 2014, 2015 and 2016 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 32,500 stock appreciation rights.
- F2On February 5, 2014, the reporting person was granted 182,500 stock appreciation rights. The stock appreciation rights are eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2016, 80% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 36,500 stock appreciation rights.